{
    "organizations": [],
    "uuid": "f5fca5d9897ad8ec8564becc7bbea3f4e93f2c49",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-united-therapeutics-to-acquire-ste/brief-united-therapeutics-to-acquire-steadymed-for-4-46-per-share-in-cash-idUSASC09Y51",
    "ord_in_thread": 0,
    "title": "BRIEF-United Therapeutics To Acquire SteadyMed For $4.46 Per Share In Cash",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30 (Reuters) - Steadymed Ltd:\n* UNITED THERAPEUTICS TO ACQUIRE STEADYMED LTD. * STEADYMED LTD - DEAL FOR $4.46 PER SHARE IN CASH\n* STEADYMED - DEAL INCLUDES ADDITIONAL $2.63/SHARE IN CASH TO UNITED THERAPEUTICS UPON ACHIEVEMENT OF MILESTONE RELATED TO COMMERCIALIZATION OF TREVYENT\n* STEADYMED LTD - TRANSACTION, INCLUDING $75 MILLION IN CONTINGENT CONSIDERATION, IS VALUED AT $216 MILLION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-30T18:10:00.000+03:00",
    "crawled": "2018-05-01T19:55:47.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "steadymed",
        "ltd",
        "united",
        "therapeutic",
        "acquire",
        "steadymed",
        "steadymed",
        "ltd",
        "deal",
        "per",
        "share",
        "cash",
        "steadymed",
        "deal",
        "includes",
        "additional",
        "cash",
        "united",
        "therapeutic",
        "upon",
        "achievement",
        "milestone",
        "related",
        "commercialization",
        "trevyent",
        "steadymed",
        "ltd",
        "transaction",
        "including",
        "million",
        "contingent",
        "consideration",
        "valued",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}